UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.411

Sortiert nach

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Hepatology (Baltimore, Md.), 2020-09, Vol.72 (3), p.892-905

2020

Link zum Volltext

Verfügbarkeit prüfen

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

PloS one, 2016-06, Vol.11 (6), p.e0158156

2016

Link zum Volltext

Verfügbarkeit prüfen

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

Expert opinion on investigational drugs, 2018-03, Vol.27 (3), p.301-311

Tacke, Frank

2018

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc: a review of its use in HIV infection and beyond

Drug design, development and therapy, 2015-01, Vol.9 (default), p.5447-5468

2015

Link zum Volltext

Verfügbarkeit prüfen

Penicillixanthone A, a marine-derived dual-coreceptor antagonist as anti-HIV-1 agent

Natural product research, 2019-05, Vol.33 (10), p.1467-1471

2019

Link zum Volltext

Verfügbarkeit prüfen

Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5

Journal of biomolecular structure & dynamics, 2022-01, Vol.40 (23), p.13115-13126

2022

Link zum Volltext

Verfügbarkeit prüfen

CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV

Expert opinion on investigational drugs, 2016-12, Vol.25 (12), p.1377-1392

2016

Link zum Volltext

Verfügbarkeit prüfen

A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action

European journal of pharmaceutical sciences, 2013-02, Vol.48 (3), p.406-415

2013

Link zum Volltext

Verfügbarkeit prüfen

Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s

Scientific reports, 2019-03, Vol.9 (1), p.4828, Article 4828

2019

Link zum Volltext

Verfügbarkeit prüfen

Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications

Current topics in medicinal chemistry, 2014-09, Vol.14 (13), p.1504

2014

Link zum Volltext

Verfügbarkeit prüfen

Function-Oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus (HIV)‑1 Entry Inhibitors

Journal of medicinal chemistry, 2015-02, Vol.58 (3), p.1452-1465

2015

Link zum Volltext

Verfügbarkeit prüfen

How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?

Biochemical journal, 2017-05, Vol.474 (10), p.1559-1577

2017

Link zum Volltext

Verfügbarkeit prüfen

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Hepatology (Baltimore, Md.), 2018-05, Vol.67 (5), p.1754-1767

2018

Link zum Volltext

Verfügbarkeit prüfen

CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments

Neurology : neuroimmunology & neuroinflammation, 2022-01, Vol.9 (1)

2022

Link zum Volltext

Verfügbarkeit prüfen

Asymmetric Synthesis of (−)-Brevipolide H through Cyclopropanation of the α,β-Unsaturated Ketone

Organic letters, 2014-10, Vol.16 (20), p.5328-5331

2014

Link zum Volltext

Verfügbarkeit prüfen

Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents

Bioorganic & medicinal chemistry letters, 2014-05, Vol.24 (10), p.2319-2323

2014

Link zum Volltext

Verfügbarkeit prüfen

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies

Antimicrobial agents and chemotherapy, 2016-01, Vol.60 (1), p.437-450

2016

Link zum Volltext

Verfügbarkeit prüfen

Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists

Organic & biomolecular chemistry, 2015-01, Vol.13 (8), p.2407-2422

2015

Link zum Volltext

Verfügbarkeit prüfen

Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV

Immunity (Cambridge, Mass.), 2017-06, Vol.46 (6), p.1005-1017.e5

2017

Link zum Volltext

Verfügbarkeit prüfen

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis

Journal of acquired immune deficiency syndromes (1999), 2016-11, Vol.73 (3), p.252

2016

Link zum Volltext

Verfügbarkeit prüfen

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Frontiers in immunology, 2022-01, Vol.12, p.816515

2022

Link zum Volltext

Verfügbarkeit prüfen

Maraviroc reduces neuropathic pain through polarization of microglia and astroglia – Evidence from in vivo and in vitro studies

Neuropharmacology, 2016-09, Vol.108, p.207-219

2016

Link zum Volltext

Verfügbarkeit prüfen

The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age

AIDS research and human retroviruses, 2015-09, Vol.31 (9), p.893

2015

Link zum Volltext

Verfügbarkeit prüfen

Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5)

Journal of medicinal chemistry, 2015-11, Vol.58 (21), p.8647-8657

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting chemokine receptors for HIV: past, present and future

Future medicinal chemistry, 2015-01, Vol.7 (17), p.2311

Fricker, Simon P

2015

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 1.411

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.269)
Mit Volltextzugriff
(1.113)

Publikationsform

Sprache

3 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cenicriviroc Treatment for Adults With Nonalcoholic Steatohepatitis and Fibrosis: Final Analysis of the Phase 2b CENTAUR Study

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis

Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis

Maraviroc: a review of its use in HIV infection and beyond

Penicillixanthone A, a marine-derived dual-coreceptor antagonist as anti-HIV-1 agent

Structure-based identification of novel scaffolds as potential HIV-1 entry inhibitors involving CCR5

CCR5 receptor antagonists in preclinical to phase II clinical development for treatment of HIV

A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action

Activity and structural analysis of GRL-117C: a novel small molecule CCR5 inhibitor active against R5-tropic HIV-1s

Chemokine receptor CCR5 antagonist maraviroc: medicinal chemistry and clinical applications

Function-Oriented Development of CXCR4 Antagonists as Selective Human Immunodeficiency Virus (HIV)‑1 Entry Inhibitors

How to win the HIV-1 drug resistance hurdle race: running faster or jumping higher?

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments

Asymmetric Synthesis of (−)-Brevipolide H through Cyclopropanation of the α,β-Unsaturated Ketone

Design, syntheses, and characterization of piperazine based chemokine receptor CCR5 antagonists as anti prostate cancer agents

Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies

Synthesis, binding affinity and structure-activity relationships of novel, selective and dual targeting CCR2 and CCR5 receptor antagonists

Structure of CC Chemokine Receptor 5 with a Potent Chemokine Antagonist Reveals Mechanisms of Chemokine Recognition and Molecular Mimicry by HIV

Brief Report: Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis

Targeting CCR5 as a Component of an HIV-1 Therapeutic Strategy

Maraviroc reduces neuropathic pain through polarization of microglia and astroglia – Evidence from in vivo and in vitro studies

The efficacy and safety of maraviroc addition to a stable antiretroviral regimen in subjects with suppressed plasma HIV-RNA is not influenced by age

Inhibition of Inflammatory and Neuropathic Pain by Targeting a Mu Opioid Receptor/Chemokine Receptor5 Heteromer (MOR-CCR5)

Targeting chemokine receptors for HIV: past, present and future

Suchergebnisse filtern